Clinical Evidence for and Cost-Effectiveness of Advanced Cellular Tissue Products for the Treatment of Diabetic Foot Ulcers
Summary: This review evaluates the clinical and economic evidence supporting advanced cellular tissue products (CTPs) as adjunctive therapies for diabetic foot ulcers. The article highlights studies demonstrating improved wound healing rates and reduced time to closure with certain CTPs compared to standard care. It also discusses economic models suggesting that CTPs may lower long-term healthcare costs by reducing complications and the need for amputations.
Key Highlights:
- CTPs, including bioengineered skin substitutes, show superior healing outcomes versus standard treatment.
- Economic analyses suggest potential cost savings through reduced infections and amputations.
- Comparative data indicate variations in cost-effectiveness across different product types.
- Further large-scale studies are needed to optimize patient selection and maximize clinical and financial benefits.
Keywords: advanced cellular tissue products, diabetic foot ulcer, cost effectiveness, wound healing, health economics